BCL2L1 and acute myeloid leukemia: The overexpression of anti-apoptotic proteins (BCL2, BCL-xL, and MCL1), which is linked to chemotherapy resistance in AML, prompted the addition of VEN to low-dose cytarabine (LDAC) or HMA therapy.